InflaRx (IFRX) Leerink Global Healthcare Conference 2026 summary

Strategic focus and restructuring

• Underwent restructuring after emergency use authorization and European approval for a COVID-related drug became less commercially relevant; focus shifted to new pipeline opportunities.

• Core team retained to drive high-quality development of new assets, particularly izicopan.

• Company is now centered on izicopan, an oral C5aR inhibitor, with plans for further development in hidradenitis suppurativa (HS) and other immunology indications.

• Actively exploring additional indications, including ANCA vasculitis, leveraging a lean and focused team.

Clinical development and data highlights

• Phase II-A open-label trial of izicopan in HS showed rapid and deepening efficacy, especially in reducing draining tunnels and pain.

• High-dose group achieved 50% of patients free of draining tunnels after four weeks; strong pain reduction observed across all dosing groups.

• Drug effects persisted after treatment cessation, suggesting potential for once-daily dosing.

• Challenges with HiSCR endpoint variability discussed; company is in dialogue with FDA to explore alternative or modified endpoints.

Regulatory and commercial strategy

• Upcoming Capital Markets Day will provide clarity on HS development path and regulatory strategy, aiming to reduce binary risk in phase II.

• Funded into mid-2027; pursuing both capital markets and strategic partnerships to support broader development.

• Engaged in discussions with pharmaceutical companies for collaborations, especially to expand izicopan into additional indications.